{
    "table": "| Methods                                                                                                                                                                                                   | Participants                                                                                                                                                                                | Interventions                                                                                            | Outcomes                                                                                                                                                                                                                                                                                                             | Notes                                                                                             |\n|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------|\n| Randomised controlled trial                                                                                                                                                                               | Postmenopausal women aged 40\u201370 years with varying risk factors for breast cancer                                                                                                           | 1 mg oral anastrozole or matching placebo daily for 5 years                                              | Primary endpoint: histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). Secondary endpoints: oestrogen-receptor-positive breast cancer, breast cancer mortality, other cancers, cardiovascular disease, fractures, adverse events, and deaths not due to breast cancer | NR                                                                                                |\n| Balanced block randomisation                                                                                                                                                                              | Women at risk: Placebo (n=3575), Tamoxifen (n=3579)                                                                                                                                         | Tamoxifen vs. Placebo                                                                                    | Breast cancer occurrence, invasive oestrogen receptor-positive breast cancer, all-cause mortality, adverse events                                                                                                                                                                                                    | Study registered with controlled-trials.com, number ISRCTN91879928                                |\n| Randomization of participants in a double-blind fashion was performed centrally by the NSABP Biostatistical Center, and participants were stratified by age, race, history of LCIS, and breast cancer RR. | Women aged 35 years and older were eligible for the study if they met specific criteria, including having a 5-year predicted risk for breast cancer of at least 1.66% or a history of LCIS. | Participants were randomly assigned to receive either 20 mg per day of tamoxifen or placebo for 5 years. | Outcomes included the rates of invasive breast cancer, noninvasive breast cancer, and invasive endometrial cancer.                                                                                                                                                                                                   | The study was designed to assess the efficacy of tamoxifen in reducing the risk of breast cancer. |\n| Randomized, placebo-controlled, double-blind trial                                                                                                                                                        | Postmenopausal women 35 years of age or older with specific risk factors                                                                                                                    | Exemestane vs. placebo                                                                                   | Incidence of invasive breast cancer, combined incidence of invasive and noninvasive breast cancers, adverse events, health-related and menopause-specific qualities of life                                                                                                                                          | Study drug and funding provided by Pfizer, no role in design, accrual, or analysis.               |\n| Blinded follow-up for more than 13 years                                                                                                                                                                  | 1238 participants in tamoxifen arm, 1233 participants in placebo arm                                                                                                                        | Tamoxifen vs. placebo                                                                                    | Incidence of ER-positive invasive breast cancer, incidence of all invasive cancers                                                                                                                                                                                                                                   | NR                                                                                                |\n| Randomized controlled trial                                                                                                                                                                               | Women at increased risk for breast cancer                                                                                                                                                   | Tamoxifen and Raloxifene                                                                                 | Invasive and noninvasive breast cancer rates                                                                                                                                                                                                                                                                         |                                                                                                   |"
}